Authors
Xin Yang, Shuping Fang, Lingqi Sun, Bingxue Xiao, Wenqi Lyu, Yuan Shi, Rong Ren, Ye Zhang, Weihong Kuang, Xiangdong Tang
Published in
Clinical drug investigation. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
Trazodone is widely prescribed off label for insomnia symptoms, but the dose range that best balances efficacy with acceptability and tolerability remains uncertain. This systematic review and dose-response meta-analysis evaluated trazodone for insomnia symptoms, with emphasis on clinically relevant dose selection.
We searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to 17 November 2025, for randomized controlled trials comparing trazodone with placebo or different trazodone doses in patients with insomnia symptoms. Dose-response relationships were evaluated using a one-stage random-effects model with restricted cubic splines. The primary outcome was subjective sleep quality; secondary outcomes were all-cause dropout rate and dropout due to adverse events.
Thirteen randomized controlled trials involving 1366 participants were included. Compared with placebo, trazodone moderately improved subjective sleep quality (Cohen's d = 0.67, 95% confidence interval [CI] 0.36-0.98; I2 = 80.86%; p < 0.01). The dose-response curve suggested that efficacy increased at lower doses and approached a plateau around 50 mg/day, although estimates in the higher-dose range were sparse and imprecise. The estimated 50% effective dose was 15.2 mg/day, and the 95% effective dose was 38.2 mg/day, but these estimates should be interpreted as exploratory rather than as precise dose targets. Conventional meta-analysis showed no clear difference in all-cause discontinuation or discontinuation due to adverse events, whereas dose-response analysis suggested a possible dose-related increase in adverse event-related discontinuation.
Trazodone was associated with short-term improvement in subjective sleep quality among heterogeneous populations with insomnia symptoms. The most observable benefit appears to occur at relatively low doses, while dose escalation may offer limited additional benefit and reduce tolerability. However, interpretation of the findings is limited by considerable clinical heterogeneity, sparse evidence at higher doses, and insufficient data on long-term efficacy and safety.
CRD420251232065.
PMID:
43018915
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0